发布求助
文献互助 智能选刊 最新文献

Cancer clinical trials最新文献

筛选
英文 中文
High-risk thyroid cancer. Prolonged survival with early multimodality therapy. 高危甲状腺癌。早期多模式治疗延长生存期。
Cancer clinical trials Pub Date : 1981-01-01
B G Durie, D Hellman, J M Woolfenden, R O'Mara, M Kartchner, S E Salmon
{"title":"High-risk thyroid cancer. Prolonged survival with early multimodality therapy.","authors":"B G Durie,&nbsp;D Hellman,&nbsp;J M Woolfenden,&nbsp;R O'Mara,&nbsp;M Kartchner,&nbsp;S E Salmon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Eleven patients with high-risk thyroid carcinoma of anaplastic or mixed anaplastic-differentiated histology were treated using an early multimodality approach. Patients were classified using the prognostic index for thyroid carcinoma developed by the EORTC. Therapy consisted of a four-drug chemotherapy combination, radioiodine (131I), and Bacille-Calmette-Guerin (BCG) immunotherapy. Treatment was designed to maximize effects against both anaplastic and differentiated tumor components. There has been prolonged disease-free survival (14+ to 73+ months) in patients with clear cell, small cell, and mixed anaplastic histologies. Currently five patients have been in complete remission for over 4 years. Treatment has been well tolerated. The long-term participation in care by a multispecialty team has produced promising results which we hope can be valuable as a basis for multicenter trials.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"67-73"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18227812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
I.V. misonidazole (NSC 261037). Report of initial clinical experience. 静脉注射米索硝唑(NSC 261037)。初步临床经验报告。
Cancer clinical trials Pub Date : 1981-01-01
J G Schwade, J M Strong, D Gangji
{"title":"I.V. misonidazole (NSC 261037). Report of initial clinical experience.","authors":"J G Schwade,&nbsp;J M Strong,&nbsp;D Gangji","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"33-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18228871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase II trial of m-AMSA in patients with small-cell lung cancer. m-AMSA在小细胞肺癌患者中的II期试验。
Cancer clinical trials Pub Date : 1981-01-01
R B Natale, R J Gralla, R E Wittes
{"title":"A phase II trial of m-AMSA in patients with small-cell lung cancer.","authors":"R B Natale,&nbsp;R J Gralla,&nbsp;R E Wittes","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"393-5"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17337451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2'-deoxycoformycin. A new anticancer agent. 2脱氧肋间型霉素。一种新的抗癌剂。
Cancer clinical trials Pub Date : 1981-01-01
D S Poster, J S Penta, S Bruno, J S Macdonald
{"title":"2'-deoxycoformycin. A new anticancer agent.","authors":"D S Poster,&nbsp;J S Penta,&nbsp;S Bruno,&nbsp;J S Macdonald","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>2'-deoxycoformycin (2'-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue. Although inactive in preclinical tumor models, 2'-dCF has shown clinical antitumor activity as a single agent in lymphoid malignancies. This drug has the added potential of being useful as a potentiator of other antitumor agents which are deactivated by ADA. It is also possible that the drug has potential as an immunosuppressive agent. Phase I studies are ongoing and phase II trials are planned to define the antitumor spectrum of this agent.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"209-13"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18067110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cis-diamminedichloride platinum(II), an effective agent in the treatment of epidermoid carcinoma of the esophagus. A preliminary report of an ongoing Southwest Oncology Group study. 顺式二胺氯化铂(II)治疗食管表皮样癌的有效药物。一项正在进行的西南肿瘤小组研究的初步报告。
Cancer clinical trials Pub Date : 1981-01-01
F J Panettiere, L Leichman, R O'Bryan, C Haas, W Fletcher
{"title":"Cis-diamminedichloride platinum(II), an effective agent in the treatment of epidermoid carcinoma of the esophagus. A preliminary report of an ongoing Southwest Oncology Group study.","authors":"F J Panettiere,&nbsp;L Leichman,&nbsp;R O'Bryan,&nbsp;C Haas,&nbsp;W Fletcher","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The southwest oncology group tested cis-platinum, given in 28-day courses of 50 mg/m2 twice, a week apart, in patients with epidermoid carcinoma of the esophagus. Currently 19 patients entered on the study are evaluable for response (15 fully evaluable). Of these, two attained complete disappearance of tumor and four had partial responses. Of the remainder, two had stable disease lasting in excess of 90 days. Hematologic toxicity has been minimal except that three patients required multiple blood transfusions for anemia not due to blood loss. Of 21 patients currently evaluable for renal toxicity, nine had mild, and three had moderate azotemia. These results suggest that, unlike what has been believed in the past, squamous cell carcinoma of the esophagus is not a chemotherapy-resistant tumor. Further evaluation of cis-platinum alone and in combination with radiotherapy and surgery are in progress.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"29-31"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18208812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made? 辅助CMF化疗治疗乳腺癌的案例。制作好了吗?
Cancer clinical trials Pub Date : 1981-01-01
S H Levitt, R A Potish
{"title":"The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?","authors":"S H Levitt,&nbsp;R A Potish","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The utility of adjuvant CMF in the treatment of breast cancer has been reanalyzed. The actual percentage of patients who benefit from adjuvant CMF has been shown to be relatively small. The widespread use of adjuvant CMF must be further examined.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"363-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18080616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase of I trial of 4'-epi-Adriamycin. 4'-肾上腺阿霉素I期临床试验。
Cancer clinical trials Pub Date : 1981-01-01
P K Schauer, R E Wittes, R J Gralla, E S Casper, C W Young
{"title":"A phase of I trial of 4'-epi-Adriamycin.","authors":"P K Schauer,&nbsp;R E Wittes,&nbsp;R J Gralla,&nbsp;E S Casper,&nbsp;C W Young","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>4'-epi-adriamycin was administered intravenously on an every-3-week schedule to 34 patients with advanced malignant tumors. Patients were treated at five dosage levels, ranging from 40 mg/m2 to 100 mg/m2. Hematologic toxicity was dose limiting. No cardiac, renal, or hepatic toxicity was observed; there were no drug-related deaths. Partial alopecia developed in all patients receiving a cumulative dose of 200 mg/m2; mild nausea and vomiting occurred in 13 patients. Although major therapeutic responses were not seen in this phase I trial, 2 of 15 patients with objectively measurable disease showed minor responses; 7 patients had stabilization of previously progressing cancer for 3 to 5+ months. A dose of 85 mg/m2 of epi-Adriamycin every 3 weeks seems an appropriate initial dose for phase II studies in patients having a performance status of 70 or higher. A starting dose of 70 mg/m2 is recommended for patients having a lower performance status.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"433-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. 丝裂霉素c、博来霉素、长春新碱和顺铂治疗晚期复发性宫颈鳞状细胞癌。
Cancer clinical trials Pub Date : 1981-01-01
D S Alberts, P W Martimbeau, E A Surwit, N Oishi
{"title":"Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix.","authors":"D S Alberts,&nbsp;P W Martimbeau,&nbsp;E A Surwit,&nbsp;N Oishi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A combination chemotherapy regimen containing mitomycin-C (10 mg/m2, day 2), vincristine (0.5 mg/m2, days 1 and 4), bleomycin (30 U QD, days 1--4 as a continuous intravenous infusion during courses one and two only), and cis-platinum (50 mg/m2, days 1 and 22) was administered every 6 weeks to 14 evaluable patients with advanced (i.e., Stage IVB) and/or recurrent squamous cell carcinoma of the cervix. Four patients (29%) achieved a complete response, lasting 8, 9.5+, 17+, and 21+ months. Three of these patients have had complete disappearance of their pulmonary metastases and one has had resolution of a large left-sided pelvic wall mass. Two additional patients (14%) had a partial response to therapy, each lasting 1.5 months. The median survival for these 14 patients was 9.0 months. The chemotherapy regimen was well tolerated. There were no drug-related deaths and no instances of severe or irreversible renal dysfunction or peripheral neuropathy. The mean lowest white blood cell and platelet counts were 4540 and 205,000 per mm3, respectively. Although severe or life-threatening thrombocytopenia occurred in only 36% patients, it appeared to be the dose-limiting toxicity of this drug combination.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"313-6"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17234848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are all stage III cancers of the ovary really cancers of the ovary? 所有的卵巢III期癌症都是卵巢癌吗?
Cancer clinical trials Pub Date : 1981-01-01
G A Omura
{"title":"Are all stage III cancers of the ovary really cancers of the ovary?","authors":"G A Omura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A recent chemotherapy trial in ovarian carcinoma raised questions about the diagnosis and staging of this disease. Review of the protocol records indicated that all 45 patients had a histologic or cytologic diagnosis of carcinoma. However, in three cases it was not stated how the primary site was determined. Another four cases were not explored, while eight others were explored, but the primary was not identified; the pathologic material was \"consistent\" with ovarian adenocarcinoma. Thus, one-third (15) of the patients had not had their primary adequately demonstrated. Published studies of advanced ovarian cancer typically refer to the FIGO staging system and imply that the primary lesion was actually identified, but review of the operative report and slide review of the primary lesion are not always described or required. Casually diagnosed cases should be labeled as such and evaluated separately.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"219-20"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18262299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group. 六甲基三聚氰胺、顺式二胺二氯铂和丝裂霉素c治疗晚期乳腺癌的评价。东南癌症研究小组的一项试点研究。
Cancer clinical trials Pub Date : 1980-01-01
D Lawson, M Moore, R Smalley
{"title":"An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.","authors":"D Lawson,&nbsp;M Moore,&nbsp;R Smalley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Eleven patients with metastatic breast cancer refractory to conventional therapy were treated with a combination of hexamethylmelamine 250 mg/m2 p.o. days 1-14, repeated at 4-week intervals; cis-platinum 30 mg/m2 I.V. q 28 days; and mitomycin-C 7.5-10 mg/m2 I.V. q 56 days. There were no complete responders and three partial responders for a response rate of 27%. Two patients (18%) had stabilization of disease for brief periods. The gastrointestinal toxicity of hexamethylmelamine was unacceptable. Recent reports that cis-platinum and hexamethylmelamine lack activity in breast cancer suggest that the activity of the combination was due to mitomycin-C alone.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"3 4","pages":"293-6"},"PeriodicalIF":0.0,"publicationDate":"1980-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17828130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信